Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Lynn Morris and Constantinos Wibmer.
Connection Strength

3,503
  1. Common helical V1V2 conformations of HIV-1 Envelope expose the a4ß7 binding site on intact virions. Nat Commun. 2018 10 26; 9(1):4489.
    View in: PubMed
    Score: 0,648
  2. Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. J Virol. 2016 Nov 15; 90(22):10220-10235.
    View in: PubMed
    Score: 0,564
  3. HIV broadly neutralizing antibody targets. Curr Opin HIV AIDS. 2015 May; 10(3):135-43.
    View in: PubMed
    Score: 0,509
  4. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021 04; 27(4):622-625.
    View in: PubMed
    Score: 0,191
  5. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv. 2021 Mar 01.
    View in: PubMed
    Score: 0,191
  6. Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope. J Virol. 2020 01 06; 94(2).
    View in: PubMed
    Score: 0,176
  7. V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. Cell Rep. 2018 12 11; 25(11):3123-3135.e6.
    View in: PubMed
    Score: 0,163
  8. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074.
    View in: PubMed
    Score: 0,143
  9. South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on a4ß7 for replication. Retrovirology. 2015 Jun 24; 12:54.
    View in: PubMed
    Score: 0,129
  10. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013 Oct; 9(10):e1003738.
    View in: PubMed
    Score: 0,115
  11. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov; 18(11):1688-92.
    View in: PubMed
    Score: 0,107
  12. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol. 2011 Nov; 85(21):11502-19.
    View in: PubMed
    Score: 0,098
  13. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol. 2009 Sep; 83(17):8925-37.
    View in: PubMed
    Score: 0,085
  14. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med. 2021 06 03; 384(22):2161-2163.
    View in: PubMed
    Score: 0,048
  15. SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies. bioRxiv. 2021 Mar 11.
    View in: PubMed
    Score: 0,048
  16. The V2 loop of HIV gp120 delivers costimulatory signals to CD4+ T cells through Integrin a4ß7 and promotes cellular activation and infection. Proc Natl Acad Sci U S A. 2020 12 22; 117(51):32566-32573.
    View in: PubMed
    Score: 0,047
  17. Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to a4ß7. PLoS Pathog. 2018 08; 14(8):e1007278.
    View in: PubMed
    Score: 0,040
  18. HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights. AIDS Res Hum Retroviruses. 2017 08; 33(8):749-759.
    View in: PubMed
    Score: 0,037
  19. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol. 2016 01 01; 90(1):76-91.
    View in: PubMed
    Score: 0,033
  20. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 May 01; 509(7498):55-62.
    View in: PubMed
    Score: 0,029
  21. Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virol J. 2013 Dec 02; 10:347.
    View in: PubMed
    Score: 0,029
  22. UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. J Virol. 2012 May; 86(9):4989-99.
    View in: PubMed
    Score: 0,026
  23. Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. J Virol. 2011 Aug; 85(15):7719-29.
    View in: PubMed
    Score: 0,024
  24. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011 May; 85(10):4828-40.
    View in: PubMed
    Score: 0,024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.